- A multicenter study showed that bermekimab, an anti-IL-1α inhibitor, is an effective treatment of atopic dermatitis (AD) in patients with moderate-to-severe disease refractory to standard therapy.
Why this matters
- In AD, ruptured keratinocytes produce IL-1α, which induces the inflammatory cascade and potentiates pain perception and pruritus.
- Bermekimab may represent an important new treatment for pruritus and moderate-to-severe AD.
- Bermekimab resulted in statistically significant improvements from baseline in all measures of disease severity after 7 weeks (P<.001 for all>
- Percentage reductions from baseline in the high-dose 400 mg group:
- Dermatology Life Quality Index (DLQI) (70%).
- Eczema Area and Severity Index (EASI) (76%).
- Global Individual Signs Score (GISS) (54%).
- Hospital Anxiety and Depression Scale-Anxiety Subscale (HADS-AS) (65%).
- HADS-Depression Subscale (HADS-DS) (59%).
- Patient-Oriented Eczema Measures (POEM) (66%).
- Severity Scoring of Atopic Dermatitis (SCORAD) (64%).
- 75% of patients had more than 4-point improvement in pruritus Numerical Rating Scale (NRS) worst and average itch scores.
- EASI 50 (82%).
- EASI 75 (71%).
- 25% of patients had more than 2-point improvement in Investigator Global Assessment (IGA) scores and reached a score of 0-1 by week 7.
- No new treatment-related adverse events were reported.
- 38 patients received subcutaneous bermekimab injections weekly (10 patients received 200 mg for 4 weeks and 28 patients received 400 mg for 8 weeks).
- Study was an open-label, proof-of-concept, multicenter study.
- Funding: XBiotech Inc.
- Small number of patients.
- Not randomized or blinded.